Next Article in Journal
Key FAD2, FAD3, and SAD Genes Involved in the Fatty Acid Synthesis in Flax Identified Based on Genomic and Transcriptomic Data
Next Article in Special Issue
Green Approach for Synthesis of Silver Nanoparticles with Antimicrobial and Antioxidant Properties from Grapevine Waste Extracts
Previous Article in Journal
The Molecular Mechanism and Therapeutic Application of Autophagy for Urological Disease
Previous Article in Special Issue
Evaluation of the Effect of Antibacterial Peptides on Model Monolayers
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 24
Issue 19
10.3390/ijms241914886
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Evaluation of Antibacterial Activity against Nosocomial Pathogens of an Enzymatically Derived α-Aminophosphonates Possessing Coumarin Scaffold

by
Paweł Kowalczyk
1,*,
Dominik Koszelewski
2,*,
Anna Brodzka
2,
Karol Kramkowski
3 and
Ryszard Ostaszewski
2
1
Department of Animal Nutrition, The Kielanowski Institute of Animal Physiology and Nutrition, Polish Academy of Sciences, Instytucka 3, 05-110 Jabłonna, Poland
2
Institute of Organic Chemistry, Polish Academy of Sciences, Kasprzaka 44/52, 01-224 Warsaw, Poland
3
Department of Physical Chemistry, Medical University of Bialystok, Kilińskiego 1 Str., 15-089 Białystok, Poland
*
Authors to whom correspondence should be addressed.
Int. J. Mol. Sci. 2023, 24(19), 14886; https://doi.org/10.3390/ijms241914886
Submission received: 12 September 2023 / Revised: 30 September 2023 / Accepted: 2 October 2023 / Published: 4 October 2023
(This article belongs to the Special Issue Antibacterial Strategies in Biomaterials: Current Progress and Challenges 2.0)
Browse Figures
Review Reports Versions Notes

Abstract

:
The purpose of the present study was to evaluate the synergistic effect of two important pharmacophores, coumarin and α-amino dimethyl phosphonate moieties, on antimicrobial activity against selected strains of multidrug-resistant nosocomial pathogenic bacteria. The previously developed enzyme-catalysed Kabachnik–Fields protocol allowed us to obtain the studied compounds with high yields which were free from metal impurities. The structure–activity relationship revealed that inhibitory activity is strongly related to the presence of the trifluoromethyl group (CF3−) in the coumarin scaffold. MIC and MBC studies carried out on six selected pathogenic bacterial strains (Gram-positive pathogenic Staphylococcus aureus (ATCC 23235) strain, as well as on Gram-negative Acinetobacter baumannii (ATCC 17978), Pseudomonas aeruginosa (ATCC 15442), Enterobacter cloacae (ATCC 49141), Porphyromonas gingivalis (ATCC 33277), and Treponema denticola (ATCC 35405)) have shown that tested compounds show a strong bactericidal effect at low concentrations. Among all agents investigated, five exhibit higher antimicrobial activity than those observed for commonly used antibiotics. It should be noted that all the compounds tested showed very high activity against S. aureus, which is the main source of nosocomial infections that cause numerous fatalities. Furthermore, we have shown that the studied coumarin-based α-aminophosphonates, depending on their structural characteristics, are non-selective and act efficiently against various Gram-positive and Gram-negative pathogens, which is of great importance for hospitalised patients.

1. Introduction

Nosocomial infections are one of the most common complications in immunosuppressed cancer patients. Today, the extensive spread of multidrug-resistant bacteria (MDR) among humans, animals, and environmental reservoirs has created new unanticipated epidemiological patterns [1]. Hospitalised patients are also affected by MDR infections, often associated with considerable morbidity, mortality, and financial burden [2]. Meticillin-resistant Staphylococcus aureus (S. aureus) (MRSA), vancomycin-resistant enterococci, and multidrug-resistant Gram-negative bacteria, such as pathogenic Enterobacter spp., are common pathogens. In all countries, some routine surgical operations and cancer chemotherapy will become less safe without effective antibiotics to protect against infections. Incorrectly selected antibiotics will not only be ineffective, but may also have a number of side effects, while the infection continues to develop, weakening the patient’s body more and more.
Despite efforts, outbreaks continue to occur. The urgent need for action is consistent with a precautionary approach, and national and international multisectoral action and collaboration should not be impeded by gaps in knowledge [3]. Nosocomial pathogens under favourable conditions can cause dangerous local or systemic infections. Staphylococcus infections can affect many areas of the human body. These bacteria can also attack subcutaneous tissues and soft tissues and even contribute to systemic infections such as endocarditis and inflamed heart valves [4,5,6,7,8]. Therefore, it is necessary to develop effective antimicrobial drugs [9]. As a result of the progressive increase in the resistance of S. aureus to methicillin (MRSA), vancomycin is the most widely used drug in infections. The emergence of vancomycin-resistant S. aureus infections means that the treatment of staph infections can become much more difficult in the future. Unlike Gram-negative bacteria, the Gram-positive pathogens develop a thick layer of peptidoglycan (PG) that surrounds the plasma membrane and protects bacteria from an unpredictable and often hostile environment (Figure 1). Furthermore, the PG layers of many Gram-positive bacteria are densely functionalised with anionic glycopolymers known as wall teichoic acids (WTAs), making them even more resistant to potential antimicrobial agents [10].
Recently, pharmacologists have focused their attention on new therapeutic agents such as coumarins [11,12,13]. Furthermore, compounds containing the structural motif 2H-chromen-2-one are well known in a variety of natural products [14,15,16,17] (Figure 1).
Based on the literature data, naturally occurring coumarins have been identified as privileged groups of compounds with antimicrobial activity (Figure 1). Therefore, it can be assumed that compounds containing the coumarin structural element in their structure can potentially be used as antimicrobial agents [18,19,20,21,22,23,24]. It is well recognised that the substitution of a hydrogen atom with fluorine in a molecule introduces minimal steric alterations due to its relatively small size, a fact that can facilitate interactions of a fluorinated biomolecule with the receptor site [25,26,27,28]. In addition, the introduction of fluorine as a most electronegative atom, which modulates the electron density of coumarin and participates as a hydrogen acceptor enhancing lipophilicities, can usually significantly alter the physicochemical properties of the molecule (such as solubility or log (P)). This could improve an antibacterial activity and stability. It can also reduce toxicity to eukaryotic cells, which improves therapeutic efficiency. In addition, substitution of hydrogen by a trifluoromethyl group could act in a similar way. In this case, the size of the CF3- group is much larger, making its contribution to hydrophobicity even greater [29,30]. The limited availability of antibiotics to treat multidrug-resistant Gram-negative and Gram-positive bacterial infections remains a serious problem. Therefore, it is imperative to develop new agents or new therapeutic strategies that are able to overcome drug resistance in these organisms. To reach this goal, there is an urgent need to design agents that are able to penetrate both outer and inner membranes protecting mentioned pathogens. One approach to overcome this involves appending or tweaking different functional groups on a lead structure, in the hope of generating more amenable derivatives with enhanced biological activity and cellular permeation. It was recently shown that, to accumulate in the Gram-negative bacteria, E. coli small molecules must contain an amine group, be amphiphilic, be rigid, and have low globularity [31]. α-Aminophosphonates are among the most common and biologically active organophosphorus compounds [32]; those with heterocyclic moieties especially show very interesting biological activities and have been used as antibacterial agents [33,34,35,36,37,38]. The appropriate combination of coumarin and phosphonate scaffolds was found to lead to the formation of compounds with the desired synergistic antimicrobial properties [39,40,41]. Our previous studies revealed that compounds possessing an aminocoumarin scaffold with fluorine and trifluoromethyl groups were effective inhibitors of the growth of various strains of LPS E. coli [42,43,44]. Thus, the objective of the present work is to identify the characteristics of the coumarin α-amino phosphonate structure that could be important for antibacterial activity against selected pathogenic strains with a particular emphasis on Gram-positive S. aureus and Gram-negative Enterobacter spp., which are responsible for nosocomial infection in all over the world. Moreover, we wanted to find compounds with both high antimicrobial activity and low selectivity for various types of pathogens. This is particularly important in cases of patients hospitalised due to infections with multidrug-resistant pathogens.

2. Results and Discussion

2.1. Chemistry

The most widely used and recognised method for the synthesis of α-aminophosphonates is the multi-component Kabachnik–Fields reaction. The usual synthetic protocol includes the condensation of equimolar amounts of three components (aldehyde, amine, and dialkyl phosphate) in organic solvents in the presence of various catalysts, mostly Lewis and Brönsted acids [45]. Unfortunately, many of the reported protocols suffer from some inconveniences, such as the stoichiometric amounts of catalysts (e.g., cancerogenic amines) or the application of toxic metal catalysts. Due to special requirements for the synthesis of biological compounds free from metal contamination, we focus on enzymatic methods [46]. Enzymes are very effective catalysts and have the advantage of being heavy-metal-free [47,48]. The target coumarin-based α-aminophosphonates 1–13 were prepared with yields of up to 92% according to the published procedure [42] (Figure 2). The structures of the compounds obtained were confirmed by NMR, provided in the Supplementary Materials (Figures S1–S26), and were consistent with published data.

2.2. Cytotoxic Studies of the Library of Coumarin α-Aminophoshonates 1–13 and Coumarin 14

The most common and serious MDR pathogens have been encompassed within the acronym “ESKAPE”, standing for Enterococcus faecium (E. faecium), S. aureus, Klebsiella pneumoniae (K. pneumoniae), Acinetobacter baumannii (A. baumannii), Pseudomonas aeruginosa (P. aeruginosa), and Enterobacter spp. (E. spp.) [49]. The antimicrobial agents available on the market have various drawbacks, such as toxicity, a narrow spectrum of activity, and the fact that some also exhibit drug–drug interactions. In view of the high incidence of infections in immune-affected patients, the demands for new antimicrobial agents with a broad spectrum of activity and good pharmacokinetic properties have increased. Thus, to achieve this goal, we decided to test coumarin α-aminophoshonates 1–14 as potential antimicrobial agents on the selected bacterial strains. The analysis of the MIC and MBC assays shows that, for all compounds tested, colour changes were observed on 48-cell culture plates [50]. The strains of Gram-positive S. aureus (ATCC 23235) are the most susceptible to a modification with these compounds (visible dilutions of 10−3 corresponding to a concentration of 0.52 µM).
The noxious activity of the 14 agents examined (Figure 2) is determined in bacterial cells, according to a previously published protocol [42], after the analysis of the MIC and MBC tests, for which the MIC values were recorded in the range of 2–8.3 µM, and the MBC values in the range of 2–9 (+/−0.5) µM for the Gram-negative investigated strains of A. baumannii (ATCC 17978), P. aeruginosa (ATCC 15442), Enterobacter cloacae (E. cloacae) (ATCC 49141), Porphyromonas gingivalis (P. gingivalis) (ATCC 33277), and Treponema denticola (T. denticola) (ATCC 35405) (Figure 3, Figure 4 and Figure 5). The minimal inhibitory concentration (MIC) defines in vitro levels of susceptibility or resistance of specific bacterial strains to the antibiotic applied. MBC is the minimal antibacterial density necessary to kill bacteria, that is, bactericidal, rather than purely bacteriostatic densities [43].
The results of our studies show that the synthesised compounds 1–13 can potentially be applied as ‘alternatives’ for antibiotics currently used in hospital and clinical infections. Therefore, studies on the antibacterial activity of newly synthesised compounds are of great importance in nosocomial or clinical infections [42,44]. Comparing the MIC values for the tested compounds 1–12 versus compound 13, we see a clear impact of the CF3 group present in the coumarin structure on the increasing antimicrobial activity (Figure 4). Additionally, the introduction of a phosphonate moiety into the studied structures significantly increases the activity against all pathogens tested (compounds 1–13 vs. 14). As we can see in Figure 3, the changes in the base structure of coumarin 14 are manifested by slight changes in the activity of the investigated α-aminophosphonates 1–14, which may indicate that the coumarin subunit is mainly responsible for the activity of these compounds against Gram-positive S. aureus (ATCC 23235). However, in the case of Gram-negative pathogens, we observe a significant dependence of antimicrobial activity on the nature of the substituent located in the phenyl ring of the revised compounds 1–13. The introduction of electron-donating groups as well as a halogen atom such as bromine or fluorine into the para-position of the phenyl ring of the studied compounds 1–5 increases the antimicrobial activity against selected Gram-negative bacteria. Note that, for other halogens, iodine, and chlorine, and electron-donating groups at the para-position, we observe a reduction in antimicrobial activity. We observe the same effect for heteroaromatic substituents and naphthyl group 6–12. We also see the influence of the location of the electron-withdrawing substituent in the aromatic ring on the antimicrobial activity. The compound with a nitro group in the meta-position shows higher activity against A. baumannii (ATCC 17978) and P. aeruginosa (ATCC 15442) than its analogue, with an identical group in the para-position (compounds 8 and 9). Finally, to our delight, tested compounds 4 and 5 reveal desired nonselective antimicrobial activity against all tested pathogens. This feature is particularly important in the fight against multidrug-resistant pathogens belonging to both Gram-positive and Gram-negative bacteria.
It should also be noted that in most cases the tested α-aminophosphonates showed higher antimicrobial activity than those of widely used antibiotics (Figure 3 and Figure 4). This is particularly important because there is a clear increase in the resistance of tested pathogens to antibiotics such as ciprofloxacin (cipro) or cloxacillin (clox) (Figure 4). It is not known in what time interval pathogens will develop resistance to bleomycins (bleo), which will significantly disrupt the arsenal of available antibiotics used in the fight against hospital infections.
Usually, antimicrobial agents are classified as bactericidal or bacteriostatic. If the MBC-MIC ratio is small (less than 4–6), a drug is considered bactericidal, and it is possible to obtain drug concentrations that kill 99.9% of the organisms exposed. If the ratio of MBC to MIC is large, it may not be possible to administer doses of the drug safely to kill 99.9% of the bacteria, and the drug is considered bacteriostatic. For many compounds, the distinction between bactericidal and bacteriostatic is not exact and depends on the drug concentration attained in the target tissue and the pathogen involved. In the case of all tested compounds 1–14, we are dealing with bactericidal agents (Figure 6).

2.3. Analysis of Bacterial DNA Isolated from S. aureus (ATCC 23235) Strain Modified with Tested Coumarin α-Aminophoshonates

The results of our current studies (MIC values) and those previously obtained [42] revealed that coumarin α-aminophoshonates show a strong toxic effect on the analysed strains of model pathogens. The compounds numbered 1–5 were revealed to be the most active against studied pathogenic cells, similar to those observed for commonly used antibiotics. (Figure 7). As can be seen in Figure 3, the studied strain of S. aureus (ATCC 23235) was sensitive to all compounds tested. The antimicrobial activity was similar to or even higher than those observed for bleomycin used as a reference (Figure 7).
Modified bacterial DNA was digested with Fpg as previously described [42,44]. All selected coumarin derivatives 1–14 (Figure 7) can strongly change the topology of bacterial DNA. After a digestion with Fpg, the base excision repair (BER) system, approximately 3.5% of the oxidative damage was identified, which indicates very strong oxidative damage in bacterial DNA. The results obtained for the individual compounds were statistically significant at the level of p < 0.05 (Table 1).
To study an oxidative stress, modified bacterial DNA was digested with a marker of oxidative stress Fpg protein from the group of repair glycosylases [42,44]. We investigated whether the resulting modifications in bacterial DNA would introduce an oxidative damage to the three DNA chain by changing the topological forms of bacterial DNA: ccc, oc, and linear forms. These results were in agreement with our previous studies [43,44]. Modification of bacterial DNA with the studied compounds led to the observation that all analysed coumarin α-aminophoshonates can strongly affect the topology of bacterial DNA, even after digestion with Fpg protein on the basis of agarose gels. The sensitivity of the S. aureus (ATCC 23235) strain to the cytotoxic effect of the compounds used and after digestion of the Fpg protein was similar to that of E. coli strains as follows: R4 > R2 > R3 > K12. This remains in agreement with our previous studies [43,44]. Blocking BER enzymes stops DNA replication and causes apoptosis of bacterial cells. In the future, cytotoxicity studies will also be performed using various cell lines and cultures to assess the biocompatibility of test compounds with active coumarin α-aminophoshonates. The dysfunction of two membranes in the model bacterial strains is an ideal model to assess the effectiveness of these compounds in relation to the antibiotics used [43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59], (Figure 8).
The mechanism of action of given chemical compounds including an α-aminophosphonates-possessing coumarin scaffold on the cells of the analysed bacteria occurs by inducing strong oxidative stress in them, consisting of the initial adsorption of the compound molecules on the cell surface of Gram-positive and Gram-negative bacteria, and then its gradual penetration and accumulation of the substance inside the microbial cell, to a level which is sufficient to obtain a toxic effect. Next comes the stage of the penetration of the compound, which depends on both the physicochemical properties and the structure of the cell covers, one of the basic functions of which is protection against the toxic activity of chemicals [51,52,53,54,55,56,57,58,59]. Therefore, the level of antimicrobial effectiveness of different classes of chemical compounds against particular groups of microorganisms varies. These compounds destabilise the bacterial cell membrane, making it more permeable to its own molecules. The compounds analysed in Gram-negative bacteria may disrupt the biosynthesis of the cell wall structure due to the binding of magnesium ions that stabilise lipopolysaccharide (LPS). The removal of Mg2+ ions by chelating compounds such as EDTA causes the release of membrane vesicles containing LPS from cells and changes the permeability of the outer membrane of bacteria [51,52,53,54,55,56,57,58,59]. In addition to disturbances in the permeability of the cytoplasmic membrane, the analysed compounds can cause the activation of autolytic enzymes and induce the formation of free radicals. The molecules of the compounds analysed enter the cytoplasm of bacterial cells, interacting with proteins and nucleic acids, causing disruption of the proper course of the replication process or cellular respiration leading to the denaturation of cytosolic proteins and nucleic acids in the cell [51,52,53,54,55,56,57,58,59].

3. Materials and Methods

3.1. Microorganisms and Media

The reference bacterial strain of Staphylococcus aureus (ATCC 23235) was provided from (LGC Standards UK) and was used according to the recommendation of ISO 11133: 2014. Acinetobacter baumannii (ATCC 17978), Pseudomonas aeruginosa (ATCC 15442), Enterobacter cloacae (ATCC 49141), Porphiromonas gingivalis (ATCC 33277), and Treponema denticola (ATCC 35405) strains were provided from the Medical University of Bialystok, Poland. These strains were used to test the antibacterial activity of the synthesised agents which is precisely described in [42]. These strains were used to test the antibacterial activity of the synthesized agents. Bacteria were cultivated in a tryptic soy broth (TSB; Sigma-Aldrich, Saint Louis, MI, USA) liquid medium and on agar plates containing TSB medium at 25 °C. Alternatively, TSB agar plates were used. The specific growth rate (μ) according to first-order kinetics was measured using a microplate reader (Thermo, Multiskan FC, Vantaa, Finland) at 605 nm in TSB medium. Lanes 1kb-ladder and Quick Extend DNA ladder (New England Biolabs, Ipswich, MA, USA) were used for the MIC and MBC tests, as described in detail in the previous work [42].

3.2. Minimum Inhibitory Concentration (MIC) and Minimum Bactericidal Concentration (MBC)

MIC and MBC were estimated using a microtiter plate method using sterile 48- or 96-well plates, which is precisely described in [42,43,44]. Briefly, MIC and MBC, defined as the lowest concentration of a bacteriostatic agent, were determined using a microtiter plate method using sterile 48- or 96-well plates. Briefly, 50 μL of the analysed compounds and the appropriate bacterial strains were added to the first row of the plate. Then, 25 μL of sterile Tryptone Soya Broth (TSB) medium was added to the other wells and serial dilutions were performed. Subsequently, 200 μL of inoculated TSB medium containing resazurin (0.02 mg/mL) as an indicator was added to all wells. TSB medium was inoculated with 106 colony-forming units (CFU)/mL (approximately 0.5 McFarland units) of the bacterial strains. Plates were incubated at 30 °C for 24 h. The changes in colour from blue to pink or yellowish with turbidity were considered positive, and the lowest concentration at which no visible change in colour occurred was MIC according to Kowalczyk et al. [44]. Each experiment (both MIC and MBC) was repeated at least three times.
To estimate MBC, a dehydrogenase activity measurement was determined by measuring the visible changes in colour of triphenyl tetrazolium chloride (TTC) to triphenyl formazan (TF). Measures of 4 mM of dense culture (approximately 109 CFU/mL) incubated in TSB medium at 25 °C for 24 h were placed in identical test tubes. Appropriate compounds were then added to the test tubes until the mixture reached a final concentration of 10–250 mg/mL. Then, the cultures were incubated at 30 °C for 1 h. The test tubes were then sealed with parafilm and incubated for 1 h at 30 °C in the dark. The lowest concentration at which no visible red colour (formazan) appeared was taken as MBC.

3.3. Statistical Analysis

All experimental data from at least three different trials (n = 3) were given as means standard error (SEM, manufacturer, Saint Louis, MO, USA). To compare pairs of means, the Tukey post hoc test was used, indicating statistical significance with * p < 0.05, ** p < 0.1, and *** p < 0.01 [44].

3.4. Chemicals

All reagents and solvents were purchased from Sigma-Aldrich, which is precisely described in [44].

3.5. General Procedure for the Synthesis of Coumarin α-Aminophosphonates 1–13

A mixture of the corresponding 7-amino-4-trifluoromethyl coumarin or 7-amino-4-methyl coumarin (1 mmol), the corresponding aldehyde (1 mmol), dimethyl phosphite (1 mmol), and Novozym 435 (80 mg) (2-Me-THF (2 mL) if noted; see Figure 2) was shaken at 200 rpm at 30 °C for 18 h. After the reaction was complete, the catalyst was separated on a glass frit funnel. The residue was washed with ethyl acetate. The combined organic phase was concentrated under vacuum. The resulting residue was purified by column chromatography (silica gel, eluent: ethyl acetate/hexanes, 6:4) to obtain the target coumarin α-aminophosphonates 1–13. The yields of the derivatives are shown in Figure 2. The structures of the products were identified by their 1H NMR and were similar to those obtained previously [44].

4. Conclusions

The antimicrobial activity of coumarin α-aminophosphonates prepared by the enzyme-catalysed Kabachnik–Fields reaction against pathogenic bacterial strains responsible for nosocomial infections was investigated. Antimicrobial activity was enhanced by the synergetic effect of two pharmacophores, coumarin, and α-amino phosphonate. The enhanced effect on the antimicrobial activity of the CF3 group present in the coumarin scaffold against model strains of S. aureus (ATCC 23235), as well as on Gram-negative A. baumannii (ATCC 17978), P. aeruginosa (ATCC 15442), E. cloacae (ATCC 49141), P. gingivalis (ATCC 33277), and T. denticola (ATCC 35405) was revealed. Moreover, a strong impact of substituents located on the phenyl ring on antimicrobial activity was observed. The conducted studies show that the activity of tested compounds may result from changes in the spatial structure of bacterial cell membranes that cause their death. Among the coumarin α-aminophosphonates, compounds 1–5 showed super-selectivity and exhibited the highest cytotoxic activity, comparable to or better than antibiotics: ciprofloxacin, bleomycin, and cloxacillin. We have shown that the tested α-aminophosphonates are compounds exhibiting high antimicrobial activity with low selectivity to target pathogens, which plays an important role in the hospitalisation of patients and in the fight against multidrug-resistant bacteria. It should be noted that the low value of the MBC–MIC ratio indicates high toxicity of the compounds tested against the pathogenic Staphylococcus aureus ATCC 23235. Thus, the desired biocidal effect is obtained at very low concentrations of the tested compounds. The application of the investigated agents leads to strong oxidative stress and inhibition of the replication apparatus, which is extremely important in the case of pathogenic strains. The search for new nontoxic compounds for human health based on coumarin derivatives and toxic to bacterial cells will become an important factor in broadly understood antibacterial therapy in the emerging new pandemics of our century. In addition, breaking resistance to antibiotics by new environmentally modified bacterial strains created by the so-called super-resistant bacteria may be a breakthrough in the neutralisation and cytotoxicity of the analysed pathogenic species.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/ijms241914886/s1.

Author Contributions

Conceptualisation, P.K. and D.K.; methodology, P.K., D.K., A.B., K.K. and R.O.; investigation, P.K. and D.K.; funding, K.K.; resources, P.K.; data curation, P.K. and D.K.; writing—original draft preparation, P.K., R.O. and D.K.; writing—review and editing, D.K., R.O. and P.K.; supervision, P.K. All authors have read and agreed to the published version of the manuscript.

Funding

This work was supported by a grant from the Medical University of Białystok Grant of National Science Center Opus 22 Nr 2021/43/B/NZ7/01903 and by National Science Center, Poland project OPUS No. 2019/33/B/ST4/01118 and SUB1/NN/22/001/2201, B.SUB.23.359, SUB/2/NN/22/001/2201. This article is based upon work from COST Action EURESTOP, CA21145, supported by COST.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

On request of those interested.

Conflicts of Interest

The authors declare no conflict of interest.

Abbreviations

MICminimum inhibitory concentration
MBCminimum bactericidal concentration
Ocopen circle
Ccccovalently closed circle
BERbase excision repair
FpgDNA-formamidopyrimidine glycosylase
TBMEtert-butyl methyl ether
CaLBCandida antarctica Lipase B

References

  1. Nordmann, P.; Naas, T.; Poirel, L. Global Spread of Carbapenemase-producing Enterobacteriaceae. Emerg. Infect. Dis. 2011, 17, 1791–1798. [Google Scholar] [CrossRef] [PubMed]
  2. Linjawi, M.; Shakoor, H.; Hilary, S.; Ali, H.I.; Al-Dhaheri, A.S.; Ismail, L.C.; Apostolopoulos, V.; Stojanovska, L. Cancer Patients during COVID-19 Pandemic: A Mini-Review. Healthcare 2023, 11, 248. [Google Scholar] [CrossRef] [PubMed]
  3. Interagency Coordination Group on Antimicrobial Resistance. No Time to Wait: Securing the Future from Drug-Resistant Infections; Report to the secretary-general of the United Nations; IACG, WHO: Geneva, Switzerland, 2019; p. 28. [Google Scholar]
  4. Liesenborghs, L.; Meyers, S.; Lox, M.; Criel, M.; Claes, J.; Peetermans, M.; Trenson, S.; Vande Velde, G.; Vanden Berghe, P.; Baatsen, P.; et al. Staphylococcus aureus endocarditis: Distinct mechanisms of bacterial adhesion to damaged and inflamed heart valves. Eur. Heart J. 2019, 40, 3248–3259. [Google Scholar] [CrossRef] [PubMed]
  5. Cartwright, K. Pneumococcal disease in western Europe: Burden of disease, antibiotic resistance and management. Eur. J. Pediatr. 2002, 161, 188–195. [Google Scholar] [CrossRef]
  6. Aronin, S.I.; Mukherjee, S.K.; West, J.C.; Cooney, E.L. Review of pneumococcal endocarditis in adults in the penicillin era. Clin. Infect. Dis. 1998, 26, 165–171. [Google Scholar] [CrossRef]
  7. Mascari, L.M.; Ross, J.M. Quantification of staphylococcal-collagen binding interactions in whole blood by use of a confocal microscopy shear-adhesion assay. J. Infect. Dis. 2003, 188, 98–107. [Google Scholar] [CrossRef]
  8. Hartleib, J.; Kohler, N.; Dickinson, R.B.; Chhatwal, G.S.; Sixma, J.J.; Hartford, O.M.; Foster, T.J.; Peters, G.; Kehrel, B.E.; Herrmann, M. Protein A is the von willebrand factor binding protein on Staphylococcus aureus. Blood 2000, 96, 2149–2156. [Google Scholar]
  9. Amador-Miranda, R.; Bertrán-Pasarell, J.; González, M.; Conde, A. Methicillin-resistant Staphyloccocus aureus in the community. Bol. Asoc. Med. P. R. 2008, 100, 21–23. [Google Scholar]
  10. Brown, S.; Santa Maria, J.P., Jr.; Walker, S. Wall Teichoic Acids of Gram-Positive Bacteria. Annu. Rev. Microbiol. 2013, 67, 313–336. [Google Scholar] [CrossRef]
  11. Kontogiorgis, C.; Detsi, A.; Hadjipavlou-Litina, D. Coumarin-based drugs: A patent review (2008–present). Expert. Opin. Ther. Pat. 2012, 22, 437–454. [Google Scholar] [CrossRef]
  12. Mustafa, Y.F.; Bashir, M.K.; Oglah, M.K. Original and Innovative Advances in the Synthetic Schemes of Coumarin-Based Derivatives: A Review. Sys. Rev. Pharm. 2020, 11, 598–612. [Google Scholar] [CrossRef]
  13. Ismael, R.M.; Mustafa, Y.F.; Al-Qazaz, H.K. Coumarin-based products: Their biodiversity and pharmacology. Iraqi J. Pharm. 2021, 18, 162–179. [Google Scholar] [CrossRef]
  14. Sarker, S.D.; Nahar, L. Progress in the Chemistry of Naturally Occurring Coumarins. Prog. Chem. Org. Nat. Prod. 2017, 106, 241–304. [Google Scholar] [CrossRef] [PubMed]
  15. Murray, R.D.H. The naturally occurring coumarins. Fortschr. Chem. Org. Naturst. 2002, 83, 1–619. [Google Scholar] [CrossRef]
  16. Soine, T.O. Naturally Occurring Coumarins and Related Physiological Activities. J. Pharm. Sci. 1964, 53, 231–264. [Google Scholar] [CrossRef]
  17. Kirsch, G.; Abdelwahab, A.B.; Chaimbault, P. Natural and Synthetic Coumarins with Effects on Inflammation. Molecules 2016, 21, 1322. [Google Scholar] [CrossRef]
  18. Borges, F.; Roleira, F.; Milhazes, N.; Santana, L.; Uriarte, E. Simple coumarins and analogues in medicinal chemistry: Occurrence, synthesis and biological activity. Curr. Med. Chem. 2005, 12, 887–916. [Google Scholar] [CrossRef]
  19. Riveiro, M.E.; De Kimpe, N.; Moglioni, A.; Vázquez, R.; Monczor, F.; Shayo, C.; Davio, C. Coumarins: Old compounds with novel promising therapeutic perspectives. Curr. Med. Chem. 2010, 17, 1325–1338. [Google Scholar] [CrossRef]
  20. Chen, S.; Cho, M.; Karlsberg, K.; Zhou, D.; Yuan, Y.-C. Biochemical and Biological Characterization of a Novel Anti-aromatase Coumarin Derivative. J. Biol. Chem. 2004, 279, 48071–48078. [Google Scholar] [CrossRef]
  21. Kulkarni, M.V.; Kulkarni, G.M.; Lin, C.-H.; Sun, C.-M. Recent Advances in Coumarins and 1-Azacoumarins as Versatile Biodynamic Agents. Curr. Med. Chem. 2006, 13, 2795–2818. [Google Scholar] [CrossRef]
  22. Al-Majedy, Y.; Kadhum, A.A.; Ibraheem, H.; Al-Amiery, A.; Moneim, A.A.; Mohamad, A.B. A Systematic Review on Pharmacological Activities of 4-Methylumbelliferon. Syst. Rev. Pharm. 2018, 9, 49–54. [Google Scholar] [CrossRef]
  23. Varga, P.R.; Dinny, S.N.M.; Szil, T.; Szak, G.; Keglevich, G. Optimized Synthesis and Cytotoxic Activity of α-Aminophosphonates against a Multidrug Resistant Uterine Sarcoma Cell Line. Lett. Drug Des. Discov. 2023, 20, 365–371. [Google Scholar] [CrossRef]
  24. Shaikh, S.; Dhavan, P.; Singh, P.; Uparkar, J.; Vaidya, S.P.; Jadhav, B.L.; Ramana, M.M.V. Design, synthesis and biological evaluation of novel antipyrine based α-aminophosphonates as anti-Alzheimer and anti-inflammatory agent. J. Biomol. Struct. Dyn. 2023, 41, 386–401. [Google Scholar] [CrossRef] [PubMed]
  25. Jäckel, C.; Seufert, W.; Thust, S.; Koksch, B. Evaluation of the Molecular Interactions of Fluorinated Amino Acids with Native Polypeptides. ChemBioChem 2004, 5, 717–720. [Google Scholar] [CrossRef]
  26. He, J.; Li, Z.; Dhawan, G.; Zhang, W.; Sorochinsky, A.E.; Butler, G.; Soloshonok, V.A.; Han, J. Fluorine-containing drugs approved by the FDA in 2021. Chin. Chem. Lett. 2023, 34, 107578. [Google Scholar] [CrossRef]
  27. Inoue, M.; Sumii, Y.; Shibata, N. Contribution of Organofluorine Compounds to Pharmaceuticals. ACS Omega 2020, 5, 10633–10640. [Google Scholar] [CrossRef]
  28. Richardson, P. Applications of fluorine to the construction of bioisosteric elements for the purposes of novel drug discovery. Expert Opin. Drug Discov. 2021, 16, 1261–1286. [Google Scholar] [CrossRef]
  29. Yan, G.; Wang, J.; Zhang, P.; Hu, L.; Wang, X.; Yang, G.; Fu, S.; Cheng, X.; Tang, R. Tunable dynamic fluorinated poly(orthoester)-based drug carriers for greatly enhanced chemotherapeutic efficacy. Polym. Chem. 2017, 8, 2063–2073. [Google Scholar] [CrossRef]
  30. Kawase, M.; Varu, B.; Shah, A.; Motohashi, N.; Tani, S.; Saito, S.; Debnath, S.; Mahapatra, S.; Dastidar, S.G.; Chakrabarty, A.N. Antimicrobial Activity of New Coumarin Derivatives. Arzneimittelforschung 2001, 51, 67–71. [Google Scholar] [CrossRef]
  31. Richter, M.F.; Drown, B.S.; Riley, A.P.; Garcia, A.; Shirai, T.; Svec, R.L.; Hergenrother, P.J. Predictive compound accumulation rules yield a broad-spectrum antibiotic. Nature 2017, 545, 299–304. [Google Scholar] [CrossRef]
  32. Varga, P.R.; Keglevich, G. Synthesis of α-Aminophosphonates and Related Derivatives; The Last Decade of the Kabachnik–Fields Reaction. Molecules 2021, 26, 2511. [Google Scholar] [CrossRef] [PubMed]
  33. Gajjala, R.R.; Chinta, R.R.; Reddy, G.V.S.; Pasupuleti, V.R.; Meenakshisundaram, S.; Balam, S.K.; Cirandur, S.R. Synthesis of New 4-Chloro-6-Methylpyrimidin-2-yl-Aminophosphonates as Potential DU145 and A549. Cancer Cell Inhib. 2020, 17, 396–410. [Google Scholar] [CrossRef]
  34. Elsherbiny, D.A.; Abdelgawad, A.M.; Shaheen, T.I.; Abdelwahed, N.A.M.; Jockenhoevel, S.; Ghazanfari, S. Thermoresponsive nanofibers loaded with antimicrobial α-aminophosphonate-o/w emulsion supported by cellulose nanocrystals for smart wound care patches. Int. J. Biol. Macromol. 2023, 233, 123655. [Google Scholar] [CrossRef] [PubMed]
  35. Maruyama, H.B.; Arisawa, M.; Sawada, T. Alafosfalin, a new inhibitor of cell wall biosynthesis: In vitro activity against urinary isolates in Japan and potentiation with beta-lactams. Antimicrob. Agents Chemother. 1979, 16, 444–451. [Google Scholar] [CrossRef]
  36. Kenawy, E.-R.S.; Azaam, M.M.; Saad-Allah, K.M. Synthesis and antimicrobial activity of α-aminophosphonates containing chitosan moiety. Arab. J. Chem. 2015, 8, 427–432. [Google Scholar] [CrossRef]
  37. Abdel-Megeed, M.F.; Badr, B.E.; Azaam, M.M.; El-Hiti, G.A. Synthesis and Antimicrobial Activities of a Novel Series of Heterocyclic α-Aminophosphonates. Arch. Pharm. 2012, 345, 784–789. [Google Scholar] [CrossRef]
  38. Poola, S.; Nagaripati, S.; Tellamekala, S.; Chintha, V.; Kotha, P.; Yagani, J.R.; Golla, N.; Cirandur, S.R. Green synthesis, antibacterial, antiviral and molecular docking studies of α-aminophosphonates. Synth. Commun. 2020, 50, 2655–2672. [Google Scholar] [CrossRef]
  39. Litim, B.; Cheraiet, Z.; Meliani, S. Synthesis and potent antimicrobial activity of novel coumarylthiazole α-aminophosphonates derivatives. Mol. Divers. 2022, 26, 1161–1174. [Google Scholar] [CrossRef]
  40. Koleva, A.I.; Petkova-Yankova, N.I.; Nikolova, R.D. Synthesis and Chemical Properties of 3-Phosphono-coumarins and 1,2-Benzoxaphosphorins as Precursors for Bioactive Compounds. Molecules 2019, 24, 2030. [Google Scholar] [CrossRef]
  41. Yang, X.-C.; Zeng, C.-M.; Avula, S.R.; Peng, X.-M.; Geng, R.-X.; Zhou, C.-H. Novel coumarin aminophosphonates as potential multitargeting antibacterial agents against Staphylococcus aureus. Eur. J. Med. Chem. 2023, 245, 114891. [Google Scholar] [CrossRef]
  42. Koszelewski, D.; Kowalczyk, P.; Brodzka, A.; Hrunyk, A.; Kramkowski, K.; Ostaszewski, R. Enzymatic Synthesis of a Novel Coumarin Aminophosphonates: Antibacterial Effects and Oxidative Stress Modulation on Selected E. coli Strains. Int. J. Mol. Sci. 2023, 24, 7609. [Google Scholar] [CrossRef] [PubMed]
  43. Koszelewski, D.; Kowalczyk, P.; Śmigielski, P.; Samsonowicz-Górski, J.; Kramkowski, K.; Wypych, A.; Szymczak, M.; Ostaszewski, R. Relationship between Structure and Antibacterial Activity of α-Aminophosphonate Derivatives Obtained via Lipase-Catalyzed Kabachnik–Fields Reaction. Materials 2022, 15, 3846. [Google Scholar] [CrossRef] [PubMed]
  44. Kowalczyk, P.; Wilk, M.; Parul, P.; Szymczak, M.; Kramkowski, K.; Raj, S.; Skiba, G.; Sulejczak, D.; Kleczkowska, P.; Ostaszewski, R. The Synthesis and Evaluation of Aminocoumarin Peptidomimetics as Cytotoxic Agents on Model Bacterial E. coli Strains. Materials 2021, 14, 5725. [Google Scholar] [CrossRef] [PubMed]
  45. Keglevich, G.; Bálint, E. The Kabachnik–Fields Reaction: Mechanism and Synthetic Use. Molecules 2012, 17, 12821–12835. [Google Scholar] [CrossRef] [PubMed]
  46. Godoy, C.A.; Pardo-Tamayo, J.S.; Barbosa, O. Microbial Lipases and Their Potential in the Production of Pharmaceutical Building Blocks. Int. J. Mol. Sci. 2022, 23, 9933. [Google Scholar] [CrossRef]
  47. Guezane-Lakoud, S.; Toffano, M.; Aribi-Zouioueche, L. Promiscuous lipase catalyzed a new P–C bond formation: Green and efficient protocol for one-pot synthesis of α-aminophosphonates. Heteroat. Chem. 2017, 28, e21408. [Google Scholar] [CrossRef]
  48. Aissa, R.; Guezane-Lakoud, S.; Kołodziej, E.; Toffano, M.; Aribi-Zouioueche, L. Diastereoselective synthesis of bis(α-aminophosphonates) by lipase catalytic promiscuity. New J. Chem. 2019, 43, 8153–8159. [Google Scholar] [CrossRef]
  49. Rice, L.B. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: No ESKAPE. J. Infect. Dis. 2008, 197, 1079–1081. [Google Scholar] [CrossRef]
  50. Maciejewska, A.; Kaszowska, M.; Jachymek, W.; Lugowski, C.; Lukasiewicz, J. Lipopolysaccharide-linked Enterobacterial Common Antigen (ECALPS) Occurs in Rough Strains of Escherichia coli R1, R2, and R4. Int. J. Mol. Sci. 2020, 21, 6038. [Google Scholar] [CrossRef]
  51. Denyer, S.P.; Stewart, G.S. Mechanisms of action of disinfectants. Int. Biodeterior. Biodegrad. 1998, 41, 261–268. [Google Scholar] [CrossRef]
  52. Gilbert, P.; Pemberton, D.; Wilkinson, D.E. Barrier properties ofthe Gram-negative cell envelope towards high molecular weight polyhexamethylene biguanides. J. Appl. Bacteriol. 1990, 69, 585–592. [Google Scholar] [CrossRef] [PubMed]
  53. Gilbert, P.; Wright, N.E. Non-Plasmidic Resistance towards Preservation of Pharmaceutical Products. In Preservatives in the Food, Pharmaceutical and Environment Industries; Board, R.G., Allwood, M.C., Banks, J.G., Eds.; Blackwell Scientific: Oxford, UK, 1987; pp. 255–279. [Google Scholar]
  54. Lambert, P.A. Mechanisms of Action of Biocides. In Russell, Hugo and Ayliffe’s Principles and Practice of Disinfection, Preservation and Sterilization, 4th ed.; Fraise, A.P., Lambert, P.A., Maillard, J.Y., Eds.; Blackwell Publishing: Oxford, UK, 2004; pp. 139–153. [Google Scholar]
  55. McDonnell, G.; Russell, A.D. Antiseptics and disinfectants: Activity, action, and resistance. Clin. Microbiol. Rev. 1999, 12, 147–179. [Google Scholar] [CrossRef] [PubMed]
  56. Stickler, D.J. Bacterial Resistance. In Russell, Hugo and Ayliffe’s Principles and Practice of Disinfection, Preservation and Sterilization, 4th ed.; Fraise, A.P., Lambert, P.A., Maillard, J.Y., Eds.; Blackwell Publishing: Oxford, UK, 2004; pp. 154–168. [Google Scholar]
  57. Vaara, M. Agents that increase the permeability of the outer membrane. Microbiol. Rev. 1992, 56, 395–411. [Google Scholar] [CrossRef] [PubMed]
  58. Widmer, A.F.; Wiestner, A.; Frei, R.; Zimmerli, W. Killing of nongrowingand adherent Escherichia coli determines drug efficacy indevice-related infections. Antimicrob. Agents Chemother. 1991, 35, 741–746. [Google Scholar] [CrossRef]
  59. Akiyama, Y. Proton-motive force stimulates the proteolytic activity of FtsH, a membrane-bound ATP-dependent protease in Escherichia coli. Proc. Natl. Acad. Sci. USA 2002, 99, 8066–8071. [Google Scholar] [CrossRef]
Ijms 24 14886 g001
Figure 1. Biologically active antimicrobial derivatives of coumarin and α-aminophosphonate. Model of antimicrobial action on Gram-positive bacteria possessing the peptidoglycan (PG) layer.
Figure 1. Biologically active antimicrobial derivatives of coumarin and α-aminophosphonate. Model of antimicrobial action on Gram-positive bacteria possessing the peptidoglycan (PG) layer.
Ijms 24 14886 g001
Ijms 24 14886 g002
Figure 2. Structures of tested coumarin based α-aminophoshonates 1–13 and control 7-amino-4-trifluoromethylcoumarin 14. a Reaction conducted in 2-Me-THF. Yields in brackets are provided for isolated products 1–13.
Figure 2. Structures of tested coumarin based α-aminophoshonates 1–13 and control 7-amino-4-trifluoromethylcoumarin 14. a Reaction conducted in 2-Me-THF. Yields in brackets are provided for isolated products 1–13.
Ijms 24 14886 g002
Ijms 24 14886 g003
Figure 3. Minimum inhibitory concentration (MIC) of the investigated agents 1–14 in selected bacterial strains. The x-axis features compounds 1–14. The y-axis shows the MIC value in µM. The order in which the compounds were applied to the plate is shown in Supplementary Materials Figure S27.
Figure 3. Minimum inhibitory concentration (MIC) of the investigated agents 1–14 in selected bacterial strains. The x-axis features compounds 1–14. The y-axis shows the MIC value in µM. The order in which the compounds were applied to the plate is shown in Supplementary Materials Figure S27.
Ijms 24 14886 g003
Ijms 24 14886 g004
Figure 4. Examples of MIC in selected bacterial strains for studied antibiotics ciprofloxacin (cipro), bleomycin (bleo), and cloxacillin (clox). The x-axis features antibiotics used sequentially. The y-axis shows the MIC value in µM.
Figure 4. Examples of MIC in selected bacterial strains for studied antibiotics ciprofloxacin (cipro), bleomycin (bleo), and cloxacillin (clox). The x-axis features antibiotics used sequentially. The y-axis shows the MIC value in µM.
Ijms 24 14886 g004
Ijms 24 14886 g005
Figure 5. Minimum bactericidal concentration (MBC) of the investigated agents 1–14 in selected bacterial strains. The x-axis features compounds 1–14. The y-axis shows the MBC value in µM. The order in which the compounds were applied to the plate is shown in Supplementary Materials Figure S27.
Figure 5. Minimum bactericidal concentration (MBC) of the investigated agents 1–14 in selected bacterial strains. The x-axis features compounds 1–14. The y-axis shows the MBC value in µM. The order in which the compounds were applied to the plate is shown in Supplementary Materials Figure S27.
Ijms 24 14886 g005
Ijms 24 14886 g006
Figure 6. The ratio of MBC/MIC of the investigated agents 1–14 in selected bacterial strains. The x-axis features compounds 1–14. The y-axis shows the MBC/MIC value in µM.
Figure 6. The ratio of MBC/MIC of the investigated agents 1–14 in selected bacterial strains. The x-axis features compounds 1–14. The y-axis shows the MBC/MIC value in µM.
Ijms 24 14886 g006
Ijms 24 14886 g007
Figure 7. Percentage of plasmid DNA recognised by the Fpg enzyme (y-axis) with the bacterial strain on the sample of the strain S. aureus (ATCC 23235) (x-axis).
Figure 7. Percentage of plasmid DNA recognised by the Fpg enzyme (y-axis) with the bacterial strain on the sample of the strain S. aureus (ATCC 23235) (x-axis).
Ijms 24 14886 g007
Ijms 24 14886 g008
Figure 8. Percentage of bacterial DNA recognised by Fpg enzyme in an example of model bacterial strains of S. aureus (ATCC 23235) after treatment with ciprofloxacin, bleomycin, and cloxacillin.
Figure 8. Percentage of bacterial DNA recognised by Fpg enzyme in an example of model bacterial strains of S. aureus (ATCC 23235) after treatment with ciprofloxacin, bleomycin, and cloxacillin.
Ijms 24 14886 g008
Table 1. Statistical analysis of all compounds analysed by MIC, MBC, and MBC/MIC; <0.05 *, <0.01 **, <0.001 ***.
Table 1. Statistical analysis of all compounds analysed by MIC, MBC, and MBC/MIC; <0.05 *, <0.01 **, <0.001 ***.
No. of Samples4, 5, 67, 8, 1011, 12, 14Type of Test
S. aureus (ATCC 23235)******MIC
S. aureus (ATCC 23235)*******MBC
S. aureus (ATCC 23235)*******MBC/MIC
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Kowalczyk, P.; Koszelewski, D.; Brodzka, A.; Kramkowski, K.; Ostaszewski, R. Evaluation of Antibacterial Activity against Nosocomial Pathogens of an Enzymatically Derived α-Aminophosphonates Possessing Coumarin Scaffold. Int. J. Mol. Sci. 2023, 24, 14886. https://doi.org/10.3390/ijms241914886

AMA Style

Kowalczyk P, Koszelewski D, Brodzka A, Kramkowski K, Ostaszewski R. Evaluation of Antibacterial Activity against Nosocomial Pathogens of an Enzymatically Derived α-Aminophosphonates Possessing Coumarin Scaffold. International Journal of Molecular Sciences. 2023; 24(19):14886. https://doi.org/10.3390/ijms241914886

Chicago/Turabian Style

Kowalczyk, Paweł, Dominik Koszelewski, Anna Brodzka, Karol Kramkowski, and Ryszard Ostaszewski. 2023. "Evaluation of Antibacterial Activity against Nosocomial Pathogens of an Enzymatically Derived α-Aminophosphonates Possessing Coumarin Scaffold" International Journal of Molecular Sciences 24, no. 19: 14886. https://doi.org/10.3390/ijms241914886

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop